Your browser doesn't support javascript.
loading
The Duration of Protection from Azithromycin Against Malaria, Acute Respiratory, Gastrointestinal, and Skin Infections When Given Alongside Seasonal Malaria Chemoprevention: Secondary Analyses of Data from a Clinical Trial in Houndé, Burkina Faso, and Bougouni, Mali.
Phiri, Mphatso Dennis; Cairns, Matthew; Zongo, Issaka; Nikiema, Frederic; Diarra, Modibo; Yerbanga, Rakiswendé Serge; Barry, Amadou; Tapily, Amadou; Coumare, Samba; Thera, Ismaila; Kuepfer, Irene; Milligan, Paul; Tinto, Halidou; Dicko, Alassane; Ouédraogo, Jean Bosco; Greenwood, Brian; Chandramohan, Daniel; Sagara, Issaka.
Afiliación
  • Phiri MD; Malaria Epidemiology Group, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
  • Cairns M; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Zongo I; Le Département Biomédical et de Santé Publique, Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.
  • Nikiema F; Le Département Biomédical et de Santé Publique, Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.
  • Diarra M; Malaria Research and Training Center, University of Science, Techniques, and Technologies of Bamako, Bamako, Mali.
  • Yerbanga RS; Le Département Biomédical et de Santé Publique, Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.
  • Barry A; Malaria Research and Training Center, University of Science, Techniques, and Technologies of Bamako, Bamako, Mali.
  • Tapily A; Malaria Research and Training Center, University of Science, Techniques, and Technologies of Bamako, Bamako, Mali.
  • Coumare S; Malaria Research and Training Center, University of Science, Techniques, and Technologies of Bamako, Bamako, Mali.
  • Thera I; Malaria Research and Training Center, University of Science, Techniques, and Technologies of Bamako, Bamako, Mali.
  • Kuepfer I; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Milligan P; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Tinto H; Le Département Biomédical et de Santé Publique, Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.
  • Dicko A; Malaria Research and Training Center, University of Science, Techniques, and Technologies of Bamako, Bamako, Mali.
  • Ouédraogo JB; Le Département Biomédical et de Santé Publique, Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.
  • Greenwood B; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Chandramohan D; Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Sagara I; Malaria Research and Training Center, University of Science, Techniques, and Technologies of Bamako, Bamako, Mali.
Clin Infect Dis ; 73(7): e2379-e2386, 2021 10 05.
Article en En | MEDLINE | ID: mdl-33417683
ABSTRACT

BACKGROUND:

Mass drug administration (MDA) with azithromycin (AZ) is being considered as a strategy to promote child survival in sub-Saharan Africa, but the mechanism by which AZ reduces mortality is unclear. To better understand the nature and extent of protection provided by AZ, we explored the profile of protection by time since administration, using data from a household-randomized, placebo-controlled trial in Burkina Faso and Mali.

METHODS:

Between 2014 and 2016, 30 977 children aged 3-59 months received seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine and either AZ or placebo monthly, on 4 occasions each year. Poisson regression with gamma-distributed random effects, accounting for the household randomization and within-individual clustering of illness episodes, was used to compare incidence of prespecified outcomes between SMC+AZ versus SMC+placebo groups in fixed time strata post-treatment. The likelihood ratio test was used to assess evidence for a time-treatment group interaction.

RESULTS:

Relative to SMC+placebo, there was no evidence of protection from SMC+AZ against hospital admissions and deaths. Additional protection from SMC+AZ against malaria was confined to the first 2 weeks post-administration (protective efficacy (PE) 24.2% [95% CI 17.8%, 30.1%]). Gastroenteritis and pneumonia were reduced by 29.9% [21.7; 37.3%], and 34.3% [14.9; 49.3%], respectively, in the first 2 weeks postadministration. Protection against nonmalaria fevers with a skin condition persisted up to 28 days PE 46.3% [35.1; 55.6%].

CONCLUSIONS:

The benefits of AZ-MDA are broad-ranging but short-lived. To maximize impact, timing of AZ-MDA must address the challenge of targeting asynchronous morbidity and mortality peaks from different causes.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Malaria / Antimaláricos Tipo de estudio: Clinical_trials Límite: Child, preschool / Humans / Infant País/Región como asunto: Africa Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2021 Tipo del documento: Article País de afiliación: Malawi

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Malaria / Antimaláricos Tipo de estudio: Clinical_trials Límite: Child, preschool / Humans / Infant País/Región como asunto: Africa Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2021 Tipo del documento: Article País de afiliación: Malawi